Table 2.
Panel of synthetic oligosaccharides used in detection of RV VP8*-oligosaccharide interactions
| Oligosaccharide conjugate | Sourcea |
|---|---|
| Lea-LC-LC | CFG |
| H type 1-LC-LC | CFG |
| H type 2-LC-LC | CFG |
| Ley-LC-LC | CFG |
| TriLex-LC-LC | CFG |
| H type 2-LC-LC | CFG |
| A tetra type 2-LC-LC | CFG |
| B tetra type 2-LC-LC | CFG |
| B tetra type 1-LC-LC | CFG |
| A tetra type 1-LC-LC | CFG |
| Lex-LC-LC | CFG |
| Lex-PAA (30 kDa) | CFG |
| Lex-PAA (1 MDa) | CFG |
| H type1-PAA (30 kDa) | CFG |
| H type1-PAA (1 MDa) | CFG |
| 3′SLea-PAA (1 MDa) | CFG |
| 3′SLex-PAA (1 MDa) | CFG |
| Tri-Lex-PAA (30 kDa) | CFG |
| Tri-Lex-PAA (1 MDa) | CFG |
| Lea-PAA | GlycoTech, Inc. |
| Leb-PAA | GlycoTech, Inc. |
| Lex-PAA | GlycoTech, Inc. |
| Ley-PAA | GlycoTech, Inc. |
| H type 1-PAA | GlycoTech, Inc. |
| H type 2-PAA | GlycoTech, Inc. |
| H type 3-PAA | GlycoTech, Inc. |
| Adi-PAA | GlycoTech, Inc. |
| Bdi-PAA | GlycoTech, Inc. |
| Atri-PAA | GlycoTech, Inc. |
| Btri-PAA | GlycoTech, Inc. |
| SLea-PAA | GlycoTech, Inc. |
| SLex-PAA | GlycoTech, Inc. |
a
CFG, Consortium for Functional Glycomics (a large research initiative funded by NIGMS to define the paradigms by which protein-carbohydrate interactions mediate cell communication [https://www.functionalglycomics.org]).